CD34+CD38− leukemic stem cell frequency to predict outcome in acute myeloid leukemia
Wendelien Zeijlemaker(Cancer Center Amsterdam), Tim Grob(Erasmus MC), Rosa J. Meijer(Erasmus MC), Diana Hanekamp(Cancer Center Amsterdam), Angèle Kelder(Cancer Center Amsterdam), Jannemieke Carbaat‐Ham(Cancer Center Amsterdam), Yvonne J.M Oussoren-Brockhoff(Cancer Center Amsterdam), Alexander N. Snel(Cancer Center Amsterdam), Dennis Veldhuizen(Cancer Center Amsterdam), Willemijn J. Scholten(Cancer Center Amsterdam), Johan Maertens, Dimitri Breems(Ziekenhuisnetwerk Antwerpen Stuivenberg), Thomas Pabst(University Hospital of Bern), Markus G. Manz(University Hospital of Zurich), Vincent H. J. van der Velden(Erasmus MC), Jennichjen Slomp(Medisch Spectrum Twente), Frank Preijers(Radboud University Nijmegen), Jacqueline Cloos(Cancer Center Amsterdam), Arjan A. van de Loosdrecht(Cancer Center Amsterdam), Bob Löwenberg(Erasmus MC), Peter J.M. Valk(Erasmus MC), Mojca Jongen‐Lavrencic(Erasmus MC), Gert J. Ossenkoppele(Cancer Center Amsterdam), Gerrit Jan Schuurhuis(Cancer Center Amsterdam)
Cited by 203Open Access